Vancouver, Canada, April  20, 2026  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (&#34;Clearmind&#34; or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel,

CMND

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Achieves Key Milestone for Alcohol Use Disorder Treatment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Vancouver, Canada, April  20, 2026  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (&amp;#34;Clearmind&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biotech company focused on the discovery and development of novel,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Clearmind Medicine Inc. announced that its CMND-100 drug candidate met primary safety endpoints in a Phase I/IIa trial for Alcohol Use Disorder. The positive results bolster confidence in advancing CMND-100 as a potential treatment, enhancing the company&#039;s position in the growing psychedelic therapeutics market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CMND-100 met primary endpoint in FDA Phase I/IIa clinical trial.</li><li>High safety profile confirmed; no serious adverse events reported.</li><li>Trial evaluates safety and efficacy for Alcohol Use Disorder treatment.</li><li>Clearmind emphasizes non-hallucinogenic compounds for mental health.</li><li>Company holds 31 granted patents and seeks further IP protection.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>BetterLife Pharma Inc. (BETR)</strong>: Engaged in similar psychedelic research; potential indirect competition for Clearmind.</li><li><strong>Compass Pathways Plc (CMPS)</strong>: Key player in the psychedelic space; contrasted against Clearmind&#039;s offerings.</li><li><strong>MindMed (MNMD)</strong>: A competitor in the psychedelic drug development field which could influence market dynamics.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it highlights significant advancements in Clearmind&#039;s clinical trials. As the company progresses towards potential commercialization, investor sentiment may shift favorably, reflecting growing confidence in its innovative treatments.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive trial results may attract institutional buyers, driving CMND&#039;s stock price higher.</li><li>Increased media coverage could lead to greater investor interest in psychedelic therapeutics.</li><li>Successful continued trials may enhance company valuation, impacting stock performance.</li><li>Any FDA news or trial expansions can create volatility in CMND&#039;s stock price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>CMND-100 is targeting Alcohol Use Disorder (AUD) with non-hallucinogenic compounds.</li><li>The ongoing Phase I/IIa trial involves multiple centers across several countries.</li><li>The third cohort showed no serious adverse events and demonstrated good tolerability.</li><li>Clearmind holds 31 patents from 19 families, focusing on neuroplastogen therapeutics.</li><li>The company’s current clinical research is part of a growing psychedelic medicine sector.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in CMND for potential upside as clinical trials progress, targeting the next 6-12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>Vancouver, Canada, April  20, 2026  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CMND">CMND</a>) ("Clearmind" or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced that CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.</p>  <p>Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated that the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and continued favorable overall tolerability, consistent with the safety outcomes observed in prior cohorts.</p>  <p>The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Meeting the primary safety and tolerability endpoint in this dose-escalation stage, including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD.</p>  <p><b>About Clearmind Medicine Inc.</b></p>  <p>Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>  <p>The Company's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>  <p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND.&#34;</p>  <p>For further information, visit: <a href="https://www.globenewswire.com/Tracker?data=TgJoN2y6BWX7I3uwIvFTqKEFljzWv5b90VxskG1cdsSl0HSi2Q8pVuLeMaun0IFJheD5UI-bRRpfQCkocM-Dnvud4S5BrU_K4n36LkBHcmjjgwZpRyzOZ_TzZ2VCw0q_" rel="nofollow" target="_blank"><u>https://www.clearmindmedicine.com</u></a> or contact:</p>  <p>Investor Relations<br></br><a href="https://www.globenewswire.com/Tracker?data=feYvnU0yijFE99kRzCLV7NYtcbFjSeVwhjAC37embiyQrRDCNsf9I4zj4mpM0iJSlvquFD7u_KTVlYIGzoqWUP7KeMI_uO-B-U5zxbrKfdXYpkappv6DKI1dVoM9kMVf" rel="nofollow" target="_blank"><u>invest@clearmindmedicine.com</u></a><br></br><a href="https://www.globenewswire.com/Tracker?data=innV1R8ZSKhKyBpBkp446nLa6EON5jQyGu6LwW_c_H3iPGygEP1vQpI7T2QY4PjC8-qE2Ms-Awa1X4f3BAxrbCdqNNegp38SaM2Llt4vnXt9saDzihVtHQjgflDqqVIB" rel="nofollow" target="_blank"><u>www.Clearmindmedicine.com</u></a></p>  <p><b>Forward-Looking Statements:</b></p>  <p>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MjkzOSM3NTQ0MzgyIzUwMDA4NjkzNA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MzI1NzlhNDAtOWEwMC00YjMxLTllNDMtMjYwNzkyMmZiMjMyLTUwMDA4NjkzNC0yMDI2LTA0LTIwLWVu/tiny/Clearmind-Medicine-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bd17cbf4-8124-4f86-8a4c-1fafbb6785af"><img src="https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg" border="0" width="150" height="23" alt="Primary Logo"></img></a></p>

Clearmind Medicine Inc. announced that its CMND-100 drug candidate met primary safety endpoints in a Phase I/IIa trial for Alcohol Use Disorder. The positive results bolster confidence in advancing CMND-100 as a potential treatment, enhancing the company's position in the growing psychedelic therapeutics market.

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News